Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT
23 mai 2022 08h00 HE | Xcelerate Inc.
AUSTIN, Texas, May 23, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Michael O’Shea, CEO of Xcelerate, Inc. (OTC Pink: XCRT, “Xcelerate”...
Cavco_Logo.png
Webcast Alert: Cavco Industries, Inc. Announces Fiscal 2022 Fourth Quarter and Year End Earnings Release and Conference Call Webcast
19 mai 2022 11h39 HE | Cavco Industries, Inc.
PHOENIX, May 19, 2022 (GLOBE NEWSWIRE) -- Cavco Industries, Inc. (Nasdaq: CVCO) will release earnings for the fourth quarter and fiscal year ended April 2, 2022 on Thursday, May 26, 2022 after the...
yield10.png
Yield10 Bioscience to Present at the H.C. Wainwright Global Hybrid Investment Conference
19 mai 2022 08h30 HE | Yield10 Bioscience, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO...
Arbutus Biopharma Logo
Arbutus to Present at H.C. Wainwright Global Investment Conference
17 mai 2022 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Obseva Logo highresolution.jpg
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
17 mai 2022 01h00 HE | ObsEva SA
-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis:...
clarus_final_indentity.jpg
Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results
16 mai 2022 16h05 HE | Clarus Therapeutics Holdings, Inc.
First quarter 2022 net revenue increased 72% year-over-year to $4.0 million First quarter 2022 total prescription growth for JATENZO® increased 12% sequentially and increased 75% year-over-year ...
CV_Sciences_logo2021.png
CV Sciences, Inc. Reports First Quarter 2022 Financial Results
16 mai 2022 09h00 HE | CV Sciences, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD)...
Obseva Logo highresolution.jpg
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
16 mai 2022 07h00 HE | ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...
Obseva Logo highresolution.jpg
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
16 mai 2022 01h00 HE | ObsEva SA
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company...
Calavo Green Circle.png
Calavo Growers to Report Second Quarter Financial Results
13 mai 2022 16h05 HE | Calavo Growers, Inc.
SANTA PAULA, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global leader in the avocado and value-added fresh food industries, today announced that it will...